Skip to content

Clinical study of low dose aripiprazole plus Minapram in the treatment of depression

Clinical study of low dose aripiprazole plus Minapram in the treatment of depression

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107599
Enrollment
Unknown
Registered
2025-08-14
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive disorder

Interventions

Experimental group:Aripiprazole
Control group:Minoxidil combined with placebo treatment

Sponsors

Jingzhou mental health center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18~65 years old; 2. Meet the ICD-10 diagnostic criteria for moderate/major depressive disorder, independently diagnosed by 2 psychiatrists with intermediate titles or above; 3. Hamilton Depression Rating Scale 17 items (HAMD-17) score >17 points; 4. Primary school education or above, able to cooperate with examination and diagnosis and treatment; 5. Right-handed; 6. Patients or family members give informed consent to this study.

Exclusion criteria

Exclusion criteria: 1. Exclude those with brain organic diseases, epilepsy and other neurological history, brain trauma or surgery; 2. Those with various serious physical diseases such as severe cardiopulmonary, hypertension, liver and kidney insufficiency and poorly controlled diabetes; 3. Clearly diagnosed schizophrenia, bipolar disorder and other mental disorders; 4. Those with psychotic symptoms such as hallucinations, delusions or depressive stiffness; 5. Those who have self-injury or suicidal behavior; 6. Those who have a history of drug and alcohol abuse; 7. Women who are pregnant, lactating and preparing for pregnancy; 8. Allergic to milnacipran or aripiprazole.

Design outcomes

Primary

MeasureTime frame
Reduction rate of Hamilton Depression Rating Scale (HAMD-17);The reduction rate of the HAMD-17 scale;

Secondary

MeasureTime frame
The ISI scale was used for assessment separately. The higher the total score, the more obvious the insomnia condition was;Evaluation of drug side effects;Each subject underwent the HAMA assessment. The higher the total score, the more obvious the anxiety state was;Blood routine test, liver and kidney function test, electrolyte test, blood sugar and lipid test, electrocardiogram test;The higher the total score of WCPA is, the more obvious the clinical physical symptoms tend to be;Assessment of the degree of suicidal ideation;

Countries

China

Contacts

Public ContactJunfeng Xu

Jingzhou Mental Health Center

742998676@qq.com+86 716 8202157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026